DNMT3A siRNA (Human)
Référence MBS8225897-15nmol
Conditionnement : 15nmol
Marque : MyBiosource
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
DNMT3A siRNA – DNA (Cytosine-5)-Methyltransferase 3a Isoform a (Human)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS8225897MBS8225897 is an siRNA targeting DNMT3A. Also known as DNMT3A siRNA (Human). Reactive in Human. Host: Synthetic. siRNA to inhibit DNMT3A expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
DNMT3A, siRNA
Full Product Name
DNMT3A siRNA (Human)
Product Gene Name
DNMT3A sirna
Product Synonym Names
DNA; cytosine-5)-methyltransferase 3A; Dnmt3a; DNA methyltransferase HsaIIIA; DNA MTase HsaIIIA; M.HsaIIIA
Host
Synthetic
Species Reactivity
Human
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
DNMT3A siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
16,866 Da
OMIM
602769
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DNMT3A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for DNMT3A sirna
RNA Interference (RNAi)
Other Notes
Small volumes of DNMT3A sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for DNMT3A. It may not necessarily be applicable to this product.
NCBI Official Full Name
DNA (cytosine-5)-methyltransferase 3A isoform a
NCBI Official Synonym Full Names
DNA (cytosine-5-)-methyltransferase 3 alpha
NCBI Official Symbol
DNMT3A
NCBI Official Synonym Symbols
TBRS; DNMT3A2; M.HsaIIIA
UniProt Protein Name
DNA (cytosine-5)-methyltransferase 3A
UniProt Synonym Protein Names
DNA methyltransferase HsaIIIA; DNA MTase HsaIIIA; M.HsaIIIA
Protein Family
DNA
UniProt Gene Name
DNMT3A
UniProt Synonym Gene Names
Dnmt3a; DNA MTase HsaIIIA; M.HsaIIIA
UniProt Entry Name
DNM3A_HUMAN
NCBI Protein Information
DNA (cytosine-5)-methyltransferase 3A
NCBI Summary for DNMT3A
CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase that is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally regulated. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
Show more UniProt Comments for DNMT3A
DNMT3A: a DNA methyltransferase required for genome wide de novo methylation and essential for development. DNA methylation is coordinated with methylation of histones. Prefers CpG methylation to CpA, CpT, and CpC methylation. Methylates CpG sites at a rate much slower than DNMT1, but greater than DNMT3b. Methylation is coordinated with methylation of histones. Binds the ZNF238 transcriptional repressor. Interacts with SETDB1 and DNMT1. Can co-localize with heterochromatin protein (HP1 ) and methyl-CpG binding protein (MeCBP). Associates with HDAC1 through its ADD-type zinc-finger. Highly expressed in fetal tissues, skeletal muscle, heart, peripheral blood mononuclear cells, kidney, and at lower levels in placenta, brain, liver, colon, spleen, small intestine and lung.
Protein type: EC 2.1.1.37; Methyltransferase, DNA; Amino Acid Metabolism - cysteine and methionine; Methyltransferase
Chromosomal Location of Human Ortholog: 2p23
Cellular Component: XY body; nucleoplasm; euchromatin; nuclear matrix; cytoplasm; nuclear heterochromatin; nucleus; chromosome, pericentric region
Molecular Function: DNA (cytosine-5-)-methyltransferase activity; identical protein binding; protein binding; DNA binding; unmethylated CpG binding; DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; metal ion binding; chromatin binding; DNA-methyltransferase activity
Biological Process: establishment and/or maintenance of chromatin architecture; genetic imprinting; DNA methylation during gametogenesis; S-adenosylhomocysteine metabolic process; negative regulation of transcription from RNA polymerase II promoter; regulation of gene expression, epigenetic; cytosine methylation within a CG sequence; methylation-dependent chromatin silencing; negative regulation of gene expression, epigenetic; DNA methylation; S-adenosylmethioninamine metabolic process; gene expression; spermatogenesis; DNA methylation during embryonic development; DNA methylation on cytosine
Disease: Tatton-brown-rahman Syndrome
Show more Protein type: EC 2.1.1.37; Methyltransferase, DNA; Amino Acid Metabolism - cysteine and methionine; Methyltransferase
Chromosomal Location of Human Ortholog: 2p23
Cellular Component: XY body; nucleoplasm; euchromatin; nuclear matrix; cytoplasm; nuclear heterochromatin; nucleus; chromosome, pericentric region
Molecular Function: DNA (cytosine-5-)-methyltransferase activity; identical protein binding; protein binding; DNA binding; unmethylated CpG binding; DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; metal ion binding; chromatin binding; DNA-methyltransferase activity
Biological Process: establishment and/or maintenance of chromatin architecture; genetic imprinting; DNA methylation during gametogenesis; S-adenosylhomocysteine metabolic process; negative regulation of transcription from RNA polymerase II promoter; regulation of gene expression, epigenetic; cytosine methylation within a CG sequence; methylation-dependent chromatin silencing; negative regulation of gene expression, epigenetic; DNA methylation; S-adenosylmethioninamine metabolic process; gene expression; spermatogenesis; DNA methylation during embryonic development; DNA methylation on cytosine
Disease: Tatton-brown-rahman Syndrome
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with DNMT3A sirna
| Reference Product | PubMed Publications |
|---|---|
| DNMT1 sirna | >566 publications with DNMT3A and DNMT1 |
| DNMT3B sirna | >563 publications with DNMT3A and DNMT3B |
| DNMT3L sirna | >120 publications with DNMT3A and DNMT3L |
| EZH2 sirna | >70 publications with DNMT3A and EZH2 |
| MYC sirna | >20 publications with DNMT3A and MYC |
| SUV39H1 sirna | >16 publications with DNMT3A and SUV39H1 |
| EED sirna | >5 publications with DNMT3A and EED |
| EHMT2 sirna | >5 publications with DNMT3A and EHMT2 |
| ZBTB17 sirna | >1 publications with DNMT3A and ZBTB17 |
Pathways associated with DNMT3A sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| Chromatin Modifying Enzymes Pathway antibodies | Chromatin Modifying Enzymes Pathway Diagram |
| Chromatin Organization Pathway antibodies | Chromatin Organization Pathway Diagram |
| Cysteine And Methionine Metabolism Pathway antibodies | Cysteine And Methionine Metabolism Pathway Diagram |
| Cysteine And Methionine Metabolism Pathway antibodies | Cysteine And Methionine Metabolism Pathway Diagram |
| DNA Methylation Pathway antibodies | DNA Methylation Pathway Diagram |
| Epigenetic Regulation Of Gene Expression Pathway antibodies | Epigenetic Regulation Of Gene Expression Pathway Diagram |
| Gene Expression Pathway antibodies | Gene Expression Pathway Diagram |
| Metabolic Pathways antibodies | Metabolic Pathways Diagram |
| Methionine Degradation Pathway antibodies | Methionine Degradation Pathway Diagram |
| Methionine Degradation Pathway antibodies | Methionine Degradation Pathway Diagram |
Diseases associated with DNMT3A sirna
| Disease Name | Pubmed Publications |
|---|---|
| Disease Models, Animal Antibodies | >38 publications with DNMT3A and Disease Models, Animal |
| Adenocarcinoma Antibodies | >37 publications with DNMT3A and Adenocarcinoma |
| Cell Transformation, Neoplastic Antibodies | >35 publications with DNMT3A and Cell Transformation, Neoplastic |
| Breast Neoplasms Antibodies | >31 publications with DNMT3A and Breast Neoplasms |
| Liver Diseases Antibodies | >29 publications with DNMT3A and Liver Diseases |
| Carcinoma, Hepatocellular Antibodies | >26 publications with DNMT3A and Carcinoma, Hepatocellular |
| Liver Neoplasms Antibodies | >23 publications with DNMT3A and Liver Neoplasms |
| Lung Neoplasms Antibodies | >22 publications with DNMT3A and Lung Neoplasms |
| Neoplasms, Experimental Antibodies | >18 publications with DNMT3A and Neoplasms, Experimental |
| Cardiovascular Diseases Antibodies | >17 publications with DNMT3A and Cardiovascular Diseases |
Organs/Tissues associated with DNMT3A sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >171 publications with DNMT3A and Blood |
| Brain Antibodies | >100 publications with DNMT3A and Brain |
| Liver Antibodies | >65 publications with DNMT3A and Liver |
| Lung Antibodies | >41 publications with DNMT3A and Lung |
| Embryonic Tissue Antibodies | >40 publications with DNMT3A and Embryonic Tissue |
| Testis Antibodies | >29 publications with DNMT3A and Testis |
| Nerve Antibodies | >26 publications with DNMT3A and Nerve |
| Muscle Antibodies | >25 publications with DNMT3A and Muscle |
| Prostate Antibodies | >25 publications with DNMT3A and Prostate |
| Skin Antibodies | >22 publications with DNMT3A and Skin |